It can happen to you
or your loved one.
At any time.
Why Does This Happen?
EARLY DETECTION IS RARE
Traditional cancer detection relies on CT or MRI scanners, which are limited.
By the time cancer is detected, millions of cancer cells will have grown and traveled around the body.
INCOMPLETE TREATMENT
Current treatments don’t usually “get it all,” allowing cancer to return.
Plus, they produce damaging side effects.
Our new technologies are being developed with the hope of earlier cancer detection, and more effective interventions, without the current side effects
​April 2024: Holobeam receives $16 million in Series A funding.
Our overall Corporate Vision is to develop ways to dramatically reduce cancer deaths
We are advancing a pipeline of promising patented medical imaging and treatment products with a focus on precision oncology.
​
With the support of government research grants and personal funding, we have conducted early-stage research using our patented and patent-pending technologies. In preclinical animal studies, we have demonstrated promising results with our new technologies, including some positive outcomes in treating cancer in mice and dogs. These findings are preliminary and require further validation through additional studies and regulatory approvals before advancing to human trials.
​
These statements do not imply any endorsement by any governmental agency.
What experts say about us
From what you’ve done so far, you have a technology that could deliver as much energy as you wanted to, to a highly specified location, which will be very valuable. Because then we could just go burn out tumors left and right,”
- Dr. Raymond Damadian
The inventor of MRI
“When somebody finds a cancer in your brain, which they can’t operate on… and they’re afraid to put radiation in it… they’ll now be able to focus it right on that point where the cancer is; the rest of your brain will never know that it happened… That, to me, is the big deal… Gene has shown that it will work, that he can actually radiate on a location and kill that location, and everything around that location: no energy at all. …We’re talking about a trillion dollar business here.”
- Dr. Anthony J. Tether
Former Director of DARPA
(the U.S. Defense Advanced Research Projects Agency)
“The technique that now is being developed by Gene to produce hyperthermic responses within the tumor, without affecting normal tissue… negates all of the other problems that have been associated with the present use of hyperthermia…”
- Dr. Myron Arlen
Founder of the Surgical Oncology Division at North Shore University (Northwell Health) Hospital
Previously practicing at Memorial Sloan Kettering Cancer Center.
Founder and Chairman of Neogenix Oncology and Precision Biologics Inc.